progestogens, 326
proglucagon, 371
progoitrin, 362
prohormones, 339
proinsulin, 364–365
prokaryote, 559
prolactin, 341, 346
prolactin inhibiting factor, 340
prolactin releasing factor, 340
proliferative retinopathy, 370
promazine, 136
promethazine, 136, 266
prontosil, 157
propantheline, 214
propofol, 280
propranolol, 14, 16, 102, 235, 259, 379, 421
6-propylthiouracil, 363
prostacyclin, 473, 519, 520
prostaglandin antagonists, 524–526
prostaglandin biosynthesis, 521
prostaglandin endoperoxide, 520–527
prostaglandin receptors, 523–524
prostaglandins, 472–473, 519, 520–527
prostate carcinoma, androgen-dependent, 324
protease inhibitors, 457, 555
protein backbone, 466
protein folding, 126
protein folding problem, 54
protein kinase A, 499–500
protein kinase C, 94–96
protein tyrosine kinases, 500
proteins, 466–469
definition, 466
non-enzyme, as drugs and targets, 513–517
types of, 466–467
proteinuria, 534
proteomics, 126, 127
proton pump inhibitor, 268
PrP, 514
PrPSC, 514
Prusiner, Stanley, 515, 547
pseudomonas infection, 567
pseudoreceptor mapping, 54
psilocin, 257
psychosis, 243
psychotomimetics, 257
PTH, 311, 360, 363–364
PTKs, 500
pulmonary oedema, 350
purine biosynthesis, 551
purine neuromodulators, 297–298
purine nucleotides, 470
putamen, 200
pyramidal system, 200
pyranoses, 476
pyrantel pamoate, 590, 591
pyrazole metabolism, 152
pyridine metabolism, 152
pyridoxine, 505–506
pyridylcarbinol, 320
pyrimethamine, 587
pyrimidine biosynthesis, 551
pyrimidine nucleotides, 470
pyrogen, 473, 525QM/MM calculations, 48–49
quantitative structure–activity relationships,
53, 140–145
quantum mechanics, 43–58
quantum medicine, 55
quantum pharmacology, 43–63, 119–121
quaternary structure, peptide, 466
quinapril, 375
quinestrol, 322
quinidine, 18, 102
quinine, 116, 102
quinolines, 580
quinolones, 580
quizapine, 254rabies, 550
raloxifene, 537
ramipril, 375
Randic indices, 143
random screening, 121
ranitidine, 18, 267
raphe nuclei, 200
rate theory of Paton, receptor, 80
rational drug design, 118, 119
receptor, 10
criteria, 68
definition, 67
history, 67
molecular properties, 85, 86
types, 92–94
receptor clustering, 91
receptor cooperativity model, 88, 89
receptor internalization, 91
receptor plasticity, 86
receptor regulation, 90–92
reductions, drug metabolism, 147–148
refecoxib, 473, 525, 526
relative configuration, 476
relaxation rate, NMR, 59
releasing factors, 340
releasing hormones, 340
remikiren, 373
renin, 311, 371, 372
renin inhibitors, 372–373
renin-angiotensin system, 371–376INDEX 645